Revenue segments as reported by the company.

Net product sales

Alliance and other revenues

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Marketing, selling and administrative

Research and development

IPRD charge - MyoKardia acquisition

Amortization of acquired intangible assets

Other (income)/ expense, net

Acquired IPRD

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Bristol-Myers

Bristol Myers Squibb Co. engages in the discovery, development, licensing, manufacture, marketing, distribution, and sale of biopharmaceutical products. It offers chemically-synthesized drugs or small molecules and products produced from biological processes called biologics. The company was founded in August 1933 and is headquartered in New York, NY.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Bristol-Myers reports robust 2022 performance and outlines growth strategies

Bristol-Myers Squibb delivered strong financial performance in 2022, with revenue growth and key product successes driving sales to $46 billion.
The company's strategic focus on portfolio expansion, market access enhancement, and operational efficiency positions it for continued growth and value creation.
Challenges around market access, legislative impacts, and expense management require strategic attention, while opportunities in product development and market expansion offer avenues for future growth.

Bristol-Myers reports robust Q1 earnings, eyes growth amid challenges

Bristol-Myers' Q1 2023 performance reflects strong sales growth and a focus on innovation, with significant progress in pipeline development and new product launches.
While facing challenges from generic competition and operational issues, the company is well-positioned to capitalize on industry advancements and strategic opportunities for growth.
By reaffirming guidance, emphasizing strategic alignment, and pursuing new therapies, Bristol-Myers demonstrates resilience and a commitment to long-term success in the pharmaceutical market.

Bristol-Myers reports robust Q2 sales and strategic growth initiatives

Bristol-Myers' Q2 performance showcased strong sales driven by new product growth and key product successes like Opdivo and Reblozyl.
While facing challenges with certain products and revenue guidance changes, the company remains confident in its financial commitments and growth outlook.
Opportunities lie in capacity ramp-up for key products, conversion strategies for patient assistance programs, and upcoming R&D insights.
Overall, Bristol-Myers' performance, strengths, and opportunities position the company for continued growth and success in the pharmaceutical market.

Bristol-Myers reports robust Q3 performance, eyes growth opportunities

Bristol-Myers Squibb's Q3 earnings call highlighted strong performance, strategic initiatives for growth, and confidence in future prospects. Despite challenges in product performance and reimbursement, the company is optimistic about market improvements and growth opportunities. Executives are focused on driving sustainable long-term growth and expanding their product portfolio.

Bristol-Myers reports robust Q4 earnings, eyes growth through strategic initiatives

Bristol-Myers' Q4 2023 showcased strong financial performance, strategic advancements, and a focus on growth drivers like Opdivo and new launches.
Despite challenges in negotiations and market dynamics, Bristol-Myers remains poised for growth through its robust product portfolio and business development strategies.
The company's emphasis on innovation, commercial execution, and clinical progress positions Bristol-Myers for sustained growth and market leadership in the pharmaceutical industry.

Bristol-Myers meets Q1 expectations, focuses on growth opportunities

Bristol-Myers Squibb's Q1 performance met expectations with strong sales growth driven by key brands and strategic acquisitions.
Despite challenges in operating expenses and interest costs impacting income, the focus on efficiency and cost savings remains a priority.
The company's strengths lie in robust sales growth of key brands, promising pipeline advancements, and strategic capital allocation plans.
Opportunities in expanding indications, new trials, and market launches position Bristol-Myers for long-term growth and competitive advantage.

Bristol-Myers reports strong Q2 performance, bullish on pipeline growth

Bristol-Myers (BMY) showcased a robust Q2 performance, emphasizing pipeline advancements and strategic capital allocation for growth and returns.
The company is confident in navigating pricing changes and improving access dynamics for key products, while focusing on transformative medicines and operational excellence.
With a positive outlook for the year, Bristol-Myers is poised to leverage opportunities in oncology, pipeline advancements, and expanding indications for key assets.

Bristol-Myers (BMY) reports strong Q3 sales and pipeline progress

Bristol-Myers Squibb (BMY) showcased robust performance with strong sales growth and positive clinical data for pipeline programs.
The company's strategic strengths lie in operational excellence, capital allocation, and commitment to sustainable growth and innovation.
Challenges include market dynamics, competition in heart failure drugs, and translating clinical data into successful drug programs.
Opportunities abound in the growing heart failure drugs market, upcoming trial data readouts, and continued focus on portfolio growth and operational efficiency.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Bristol Myers Squibb Co. engages in the discovery, development, licensing, manufacture, marketing, distribution, and sale of biopharmaceutical products. It offers small molecules, products produced from biological processes called biologics, and chimeric antigen receptor (CAR-T) cell therapies. The company was founded in August 1933 and is headquartered in Princeton, NJ.

Bristol-Myers Squibb Prescribed For The Newborn Portfolio

Bristol-Myers Squibb Co. BMY, +0.98% late Thursday announced a 9.8% dividend increase, beginning in the first quarter of 2020.

Bristol-Myers Squibb raises dividend

Bristol-Myers (BMY) is well positioned to outperform the market, as it exhibits above-average growth in financials.

3 Reasons Why Growth Investors Shouldn't Overlook Bristol-Myers (BMY)

The FDA grants Breakthrough Therapy designation to Bristol-Myers Squibb's (BMY) Orencia for the prevention of moderate-to-severe acute GvHD in hematopoietic SCT from unrelated donors.

Bristol-Myers' Orencia Gets Breakthrough Therapy Tag for GvHD

Shopify

Walmart

Options trading was buzzing in Bristol-Myers Squibb, Shopify and Walmart stock on Wednesday. Here are the metrics that matter moving forward.

Thursday’s Vital Data: Bristol-Myers Squibb, Shopify and Walmart

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.

Is Bristol-Myers Squibb (BMY) a Great Value Stock Right Now?

Bristol-Myers (BMY) and Acceleron Pharma Inc.'s sBLA for Reblozyl in patients with myelodysplastic syndromes will be reviewed by the FDA's Oncologic Drugs Advisory Committee.

Bristol-Myers' Reblozyl to be Reviewed by FDA Committee

Arconic

Medtronic

Science Applications International

Target

Investors target stocks that have been on a bullish run lately. Stocks seeing price strength have a high chance of carrying the momentum forward.

5 High-Flying Stocks Near 52-Week High With More Room to Run

Celgene

Pharmaceutical company Bristol-Myers has risen this year despite shareholder opposition to its Celgene buyout. Now that Bristol has officially acquired Celgene, is it time to buy BMY stock?

Bristol-Myers Has Now Acquired Celgene — So, Should You Buy BMY Stock?

GlaxoSmithKline

Merck

Pfizer

Roche Holding AG

Large-Cap Pharmaceuticals Industry Prospects Bright for 2020

Gogo

Roku

Bank of America

Roku, Bristol-Myers Squibb, Bank of America and Gogo were our top stock trades for Tuesday. Here's a look at the charts.

4 Top Stock Trades for Tuesday: ROKU, GOGO, BAC, BMY

ArQule

Eli Lilly

These companies have some important presentations scheduled for the last big oncology conference of the year.

3 Biotech Stocks With a Lot to Prove at ASH 2019

AbbVie

Allergan

Jazz Pharmaceuticals

Zoetis

Pharmaceutical stocks rose a single-digit percentage in the first 11 months of 2019, well below their gain for 2018. Still, there are standout companies among the industry group.

Which Pharmaceutical Stocks Are Outperforming All Other Stocks?

Abbott Labs

Dollar General

These stocks are great picks to own regardless of which turns the market takes.

3 Stocks to Buy Ahead of the Next Market Crash: ABT, BMY & DG

Bristol-Myers Squibb’s (NYSE: BMY) R&D expenses were 36% of its total revenues in 2018. Total expenses were largely driven by cost of goods sold and research and development (R&D), which together accounted for three-fourths of the company’s total expenditure in 2018.

What Percent Does Bristol-Myers Squibb Spend On R&D, 30%, 40%, Or 50%?

Bristol-Myers Squibb shows rising price performance, earning an upgrade to its IBD Relative Strength Rating from 80 to 83.
The post Bristol-Myers Squibb Meets 80-Plus Relative Strength Rating Benchmark appeared first on Investor's Business Daily.

Bristol-Myers Squibb Meets 80-Plus Relative Strength Rating Benchmark

Apple

Amazon

Chipotle

CVR Energy

Alphabet

Procter & Gamble

Tesla

Vanguard FTSE Emerging Markets ETF

Billionaire-owned companies perform twice as well as others. Turns out the world's wealthiest and most powerful make for good investors.

10 Stocks Owned by the World’s Richest and Most Powerful

Teva Pharmaceutical

Pharmaceutical companies usually are involved in a lengthy process of getting their drug candidates to market through clinical trials.

Big Pharma Short Sellers Hike Their Bets

There are two reasons this Fool isn't selling his newfound shares from the Celgene buyout.

Why I'm Holding On to My Bristol-Myers Squibb Shares Now That the Celgene Acquisition Has Closed

Amgen

These two dividend-paying pharma stocks are basically immune to the whims of the broader economy.

2 Stocks to Buy If You're Worried About a Recession

AerCap Hlds

Exelixis

XPO Logistics

These are businesses with great growth potential that are trading at significant discounts.

3 Stocks - Peter Lynch Would Love.

Bristol-Myers' (BMY) late-stage study evaluating the Opdivo-Yervoy combo fails to meet a co-primary endpoint of recurrence-free survival in melanoma patients. The company wraps up Celgene acquisition.

Bristol-Myers' Melanoma Study Misses Goal, Closes Celgene Deal

Bristol-Myers Squibb Co. BMY, -0.12% on Wednesday said it completed its $74 billion acquisition of Celgene Corp.

Bristol-Myers Squibb completes $74 billion acquisition of Celgene

Bristol-Myers Squibb Co. shares BMY, -2.03% slid 0.9% in premarket trade Wednesday, after the drug company said a trial of opdivo plus yervoy in treating patients who have had surgery to treat melanoma failed to meet its main goal.

Bristol-Myers stock slides premarket after melanoma trial fails to meet main goal

Celgene: Bargain Bin At Bristol-Myers Squibb Deal Closing

News for Bristol-Myers Stock (BMY)